Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Finding Your Motivation: Moves toward a Satisfying Life - 2Brilliant and Gleaming: Excellence and Skincare Practices
- 3Favored Vehicle for Seniors: Make Your Determination
- 4Tech for Efficiency: Applications and Apparatuses to Accomplish More
- 5Explainer-What has happened to the damaged spacecraft at China's space station?
- 6 Arranging Administrations to Change Your Open air Space
- Lebanon’s Hezbollah and Yemen’s Houthis join Iran in strike on Israel
- The 15 Best Business visionaries Under 40
- Bitcoin momentum builds in Abu Dhabi as global interest surges
- Germany paves the way for tighter EU asylum rules
- Iran's stolen futures: The arrested Iranians at risk of execution by the regime
- 'Spending more on gas than groceries:' Rising fuel prices drive more San Antonio families to the Food Bank amid Iran war
- The most effective method to Settle on Informed Conclusions about Senior Insuranc.
- Netanyahu vows to ‘return Negev to Israel,’ pledges settlement growth during visit
